Growth in microscope solutions and industrial equipment
First written in FY2016. 3 of 8 entries say "Restated". Latest entry: 2026-10-28.
0 other companies' latest entry also says "Reframed".
- 2026-10-28Advancednewspicks.com
「測定順序を自動で最適化、ニコンがJIMTOF 2026で「NEXIV」の新機能を披露」
産業機器分野のNEXIVに測定順序を自動最適化する新機能が追加され、展示会で披露されたと報じられた。 - FY2018-Q2ReframedAnnual report
「Effective 29 June 2017, we established a new Healthcare Division by integrating the Microscope Solutions Business, which had previously been included in the Instruments Business, and the Medical Business. The aim was to quickly integrate and optimize the organization and functions, create business synergies, strengthen existing businesses and accelerate the creation and development of new businesses in the health, medical and biotechnology fields, where growth is expected.」
The company shifted from its previous framework, which treated Microscopy Solutions as a standalone growth area, to a healthcare business integrating the medical and biotechnology fields in order to accelerate growth. - FY2018-Q1RestatedAnnual report
「In the microscopy field of the Instruments Business, sales declined despite firm domestic performance, due mainly to delays in the execution of government budgets in the United States and China. Profit also declined, reflecting increased upfront investment in regenerative medicine-related activities. In the industrial equipment field, sales increased on the recovery of market conditions in the United States and Asia, but profit declined due in part to higher expenses to expand sales and strengthen development.」
Microscopy remained sluggish because of delays in the execution of overseas government budgets, while industrial equipment posted higher sales as market conditions recovered in the United States and Asia. Conditions in the growth areas therefore remain divergent by field and region. - FY2017AdvancedAnnual report
「We developed and launched the ECLIPSE Ti2 research inverted microscope as the successor to the ECLIPSE Ti.」
In the Microscopy Solutions Business, this led to the commercialization of a specific product, the development and launch of the successor model ECLIPSE Ti2. - FY2017-Q3RestatedAnnual report
「In the Instruments Business, the microscopy-related field was affected by delays in the execution of public budgets in Europe and the United States, but remained firm in Asia. In the industrial equipment-related field, capital investment remained sluggish due to delays in the overall economic recovery and other factors.」
Microscopy remained firm in Asia, while sluggish market conditions and capital investment continued in Europe, the United States and the industrial equipment field. - FY2017-Q2SoftenedAnnual report
「The growth businesses are expanding, but progress is not in line with expectations.」
The company explained that although the growth businesses are expanding, progress has not been in line with expectations. - FY2017-Q1RestatedAnnual report
「In the Instruments business, the microscope-related field was sluggish in Japan and Europe but performed steadily in Asia. In the industrial equipment-related field, capital investment was sluggish in the United States and Asia.」
While microscopes performed steadily in Asia, some markets were sluggish depending on the region and field, and the business continued to be described as a growth business. - FY2016First statedAnnual report
「In the Instruments business, which we position as a growth business, the microscope-related market as a whole was sluggish, but our business performed steadily as we expanded our market share.」
We position the expansion of microscope-related market share and the expansion of industrial equipment as growth areas.